Compare Adaptive Biotechnologies Corp (ADPT) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Oatly Group AB - ADR — how do they compare? Adaptive Biotechnologies Corp trades at $19.9 (market cap $3.33B), while Oatly Group AB - ADR trades at $9.48 (market cap $301.32M). The key difference: Adaptive Biotechnologies Corp is far larger — about 11.1× Oatly Group AB - ADR's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals.
| ADPT | OTLY | |
|---|---|---|
Market Cap | $3.33B | $301.32M |
Sector | Health | Consumer Staples |
52-Week High | $22.37 | $18.54 |
52-Week Low | $10.24 | $8.03 |
Enterprise Value | $3.19B | $798.94M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
OTLY trades at $9.65, down 3.02% today, with a bullish technical signal from moving averages and ADX indicators. Revenue grew to $862.46M in 2025, but the company reported a net loss of $152.77M, with negative cash flow and high debt levels. Recent news includes a partnership with Nespresso and upcoming Q2 2026 earnings on July 22, 2026.
The outlook remains challenging due to persistent losses and cash burn, though revenue growth and a strong brand offer potential. Key risks include high leverage and competitive pressures. Analysts are divided, with 44% buy ratings but 50% hold, reflecting cautious optimism amid financial headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
